TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)
Brief Summary: Assess tolerability, transition methods and clinical effects of transition from sildenafil (Revatio) to tadalafil (Adcirca) for treatment of pulmonary arterial hypertension.


Options:
A: Inclusion Criteria:

* Subjects aged 18 and over above with PAH and for which bosentan therapy is indicated according to national license
* Subjects with a mean pulmonary artery pressure of \>25mmHg and a pulmonary artery wedge pressure of \<15mmHg at rest via right heart catheterization within 3 years prior to randomization.
* Subjects whose baseline 6 Minute Walk Test distance is \>100m and \< 450m.

Exclusion Criteria:

* PAH secondary to any aetiology including congenital heart disease other than those specified in the inclusion criteria
* Subjects whose 6 Minute Walk Test may be limited by conditions other than PAH related dyspnoea or fatigue eg. claudication from vascular insufficiency or arthritis.
B: Inclusion Criteria:

* COPD (FEV1/FVC\<0.7)
* Age 40-75
* Pulmonary hypertension (Vmax TI\>=2.8m/sec)

Exclusion Criteria:

* Treatment with CYP3A4 inhibitors, nitrates, PDE-5 inhibitors
* Coronary disease
* Ischemic optical neuritis
C: Inclusion Criteria:

* Patients with PAH who had completed the 12 week pivotal study

Exclusion Criteria:

* Any other patients with PAH that had not been included into the pivotal study
D: Inclusion Criteria:

* Treatment for PAH with sildenafil at a dose of 20mg tid or greater for at least 30 days
* Clinical decision to convert from sildenafil to tadalafil therapy
* Patient consents to study participation (for patients who have already transitioned from sildenafil to tadalafil therapy prior to study initiation or identification of the patient, if the patient has provided consent for use of their medical record for research, retrospective review of the transition process will be performed. When possible, these patients will be approached about prospective data collection for the study if the transition occurred less than 3 months prior to consideration of prospective study participation)

Exclusion Criteria:

* Non-group I PAH
* Age less than 18

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Outlook: An Intervention to Improve Quality of Life in Serious Illness Study
Brief Summary: The purpose of this study is to determine whether discussions of life story, forgiveness, and future goals improve quality of life for patients with serious illness.


Options:
A: Inclusion Criteria:

* Patients with
* Advanced cancer
* Congestive heart failure
* COPD
* End stage renal disease

Exclusion Criteria:

* Cognitive impairment
* inability to speak
* non-English speaking
B: Inclusion Criteria: (1) age between 50 and 80 years; (2) a post-bronchodilator forced expiratory volume in one second (FEV1) \< 80% of the predicted value and a FEV1/ forced vital capacity (CVF) ratio \< 0,7; (3) stable respiratory/clinical condition without changes in medication and symptoms (dyspnea, volume or color of sputum) for at least 4 weeks before admission to the study; and (4) receiving regular treatment with inhaled bronchodilators and steroids.

Exclusion Criteria: (1) presence of other pulmonary, cardiovascular or musculoskeletal diseases; (2) previously participation in any exercise-training program in the last 2 years before participating in this study; and (3) current smokers.
C: Inclusion Criteria:

* COPD and/or HF diagnosis; confirmation based upon medical chart review.
* clinically significant symptoms for anxiety and/or depression.

Exclusion Criteria:

* cognitive impairment
* presence of bipolar, psychotic or substance abuse disorder.
D: Inclusion Criteria:

One or more of the following:

* Hospital admission for COPD within the prior year
* Unscheduled visit for COPD within the prior year
* Home oxygen use for COPD
* Systemic steroid use for COPD within the prior year
* Post bronchodilator FEV1 \< 70% predicted
* Post bronchodilator FEV1/FVC \< 70% predicted

Exclusion Criteria:

* Any unstable medical condition that would preclude effective participation in the study, or which would be expected to reduce life expectancy to \< 1 year
* Inability to contact patient by telephone

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: For Moms: Culturally Relevant Treatment Services for Perinatal Depression
Brief Summary: The study will evaluate the effectiveness of a culturally relevant, multi-component intervention for antenatal depression. The intervention includes an engagement session, and the woman's choice of brief interpersonal psychotherapy and/or pharmacotherapy in a stepped care treatment for depression model.


Options:
A: Inclusion Criteria:

* Recipients of TANF cash benefits for four years or less, and
* Subject to mandatory TANF 20-hour work requirement, and
* Parents of at least one child below the age of six

Exclusion Criteria:

* Adults who are unable to provide consent
B: Inclusion Criteria:

* 4-6 weeks postpartum
* English-speaking
* Score of at least 10 on the Edinburgh Postnatal Depression Scale

Exclusion Criteria:

* DSM-IV diagnosis of bipolar disorder or psychotic episode
* Active substance abuse within 6 months prior to study entry
* Has not received obstetrical care
* History of a suicide attempt within 6 months of study entry
C: Inclusion Criteria:

* 18 or older
* pregnant: 12-32 weeks gestation
* able to speak English
* telephone access
* major depressive disorder or dysthymia
* on Medicaid
* receiving health care in King County, Washington

Exclusion Criteria:

* currently in psychotherapy
* currently receiving pharmacotherapy from a psychiatrist
* high suicide risk
* history of bipolar disorder
* history of schizophrenia
* substance use or dependence in previous 3 months
* currently in a relationship with severe interpersonal violence
* history of repetitive self-harm behavior
D: Inclusion Criteria: Parent/Caregivers must meet the following criteria to be eligible to move on to Consent

1. Be a parent/caregiver of a neurodiverse child
2. Be at least 18 years of age
3. Be able to understand spoken and written English at a Grade 8 level
4. Fulfill the criteria of full or subclinical PTSI according to DSM-5, measured with the Life Events Checklist for DSM-5, the Parent Trauma Checklist and the PTSD Checklist for DSM-5. For this they have to report at least one traumatic event in the LEC-5 or the Stressful Life Experiences of Parents Checklist. To fulfill all PTSI criteria, the participant additionally needs to respond with "moderately" or higher in at least one item for the criteria B and C and two items for criteria D and E. Subclinical PTSI is fulfilled if the participant meets all but one criterion of B, C, D, or E is not met.
5. Have access to a computer with high speed Internet
6. Live in Canada
7. Commit to the requirements of taking part in the study (12 weekly coaching calls)

Exclusion Criteria:

1. Acute suicidal behavior or other extreme forms of self-destructive behavior
2. Moderate to severe symptoms of dissociation
3. Acute psychotic symptoms
4. Previously participated in exposure intervention for PTSI/PTSD

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Preventing Excessive Weight Gain by Reducing Carbonated Beverage and Sugar Consumption and Increasing Physical Activity Among Public School Adolescents From the Metropolitan Area of Rio de Janeiro
Brief Summary: The main objective is to evaluate the effect on BMI of a school-based program that discourages the consumption of all sweetened beverages, encourages the reduction in sugar intake, and encourages the increase in physical activity among adolescents and their families from a low socioeconomic area.


Options:
A: Inclusion Criteria:

* 11-13 years old
* school-going
* willing to participate

Exclusion Criteria:

* pregnant
* severe medical/physical disorder
B: Inclusion Criteria:

* Self-identified, English-speaking
* Low-income, adolescent
* First-time mothers between the ages of 14 and 19
* With daily web access and access to a cell phone that includes text messaging capabilities
* Family income ≤ 185% of federal poverty
* Term birth (37≤42 weeks, 2500≤3750 grams birth weight)
* Mothers and infants with no special nutrients or feeding needs
* Infants less than six weeks old at study enrollment who have not started eating solid foods
* Adolescent mothers must be a primary caretaker of the infant who feeds her infant at least once a day, and who is willing to participate in a six-week intervention with data collection at three defined time points (T1, T2, and T3)

Exclusion Criteria:

* Male caregivers
* Mothers and infants with diagnosed feeding/eating disorders
* Significant perinatal or postnatal complications
* Post partum depression or other mental health problems
* Adolescent mothers who do not share in the feeding responsibility of their infants
* Adolescents without daily web access nor a cell phone with text messaging capabilities
C: Inclusion Criteria:

* 5th grades

Exclusion Criteria:

* Pregnancy
D: Inclusion Criteria:

* Children in the 1. grade of secondary General Schools or Intermediate Schools with written consent from the parents in the greater Munich area

Exclusion Criteria:

* Children without written consent from their parents

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery(TEG-CABG Trial):Does Intensified Postoperative Antiplatelet Therapy in Preoperatively Identified Hypercoagulable Patients Improve Outcome After CABG Surgery
Brief Summary: The purpose of this study is to determine whether adding clopidogrel to aspirin after coronary bypass operation (CABG) improves graft patency, in patients that have preoperatively increased platelet activity(hypercoagulable) and therefore greater risk of graft occlusion( thrombosis).


Options:
A: Inclusion Criteria:

* Patients ungergoing coronary artery bypass grafting using cardiopulmonary bypass
* Patients from 18 to 85 years old.

Exclusion Criteria:

* Patients incapable to consent.
* Known coagulopathies or platelet dysfunction.
* Patients treated with antiplatelet drugs other than aspirin.
* Patients treated with anti vitamine K anticoagulants.
* Patients treated with heparin less than 6 hours prior to surgery.
B: Inclusion Criteria:

* age \> 18 years, combined surgical procedures (ACB \& valve surgery), double valve surgery, aortic surgery, Re-Dos

Exclusion Criteria:

* none
C: Inclusion Criteria:

* Males and Females
* Age 6 months to 17 years
* Scheduled for elective scoliosis surgery or major craniofacial surgery
* Written informed consent has been obtained
* Intraoperative hypofibrinogenemia according to definition of treatment groups

Exclusion Criteria:

* Preexisting congenital or acquired coagulation disorder
* Medical history of estimated increased bleeding tendency
* Ongoing coagulation therapy
* Clinical signs or diagnosis of acute thromboembolism
* Intolerance of study drug
* Participation at another clinical trial
* Pregnant or lactating women
D: Inclusion Criteria:

* Elective/subacute multivessel CABG
* Isolated CABG procedure, no concomitant surgery
* age \> 18 years
* Able to give informed consent

Exclusion Criteria:

* Myocardial infarction \<48h of surgery
* Prior CABG surgery within 1 month
* Cardiac Shock within 48h of surgery
* Atrial fibrillation
* Anticoagulation therapy with VKA
* ICH/TCI within 30 days
* Prior peptic ulcer· Platelet count \< 150 E9
* Ongoing bleeding
* Known platelet disease
* Allergic to aspirin or clopidogrel
* Liver disease with elevated ALAT/ASAT\> 1,5x normal
* Creatinine\> 0,120mmol/l
* Contrast allergy
* Alcohol or narcotics abuse
* Pregnancy
* Not able to give informed consent
* Geographically not available for follow up

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Myo-inositol May Prevent Gestational Diabetes in Obese Women
Brief Summary: Myo-Inositol is classified as a member of the vitamin B complex. It is a constituent of living cells and is widespread in many food. It is involved in a number of biological processes, including insulin signal transduction, resulting in modulating insulin sensitivity. This is a prospective, randomized, double center, placebo-controlled study. Two hundred and twenty obese pregnant women will be included in the trial and, after an informed consent, will assume randomly 2 g of myo-inositol twice a day or placebo from 12-13th weeks gestation until delivery. Then,they will perform an Oral Glucose Tolerance Test (OGTT) at 24-28th weeks gestation. Records about delivery (gestational age, neonatal weight...) will be registered.


Options:
A: Inclusion Criteria:

60 women in their first trimester of pregnancy affected by one or more of the following risk factors:

* Glycemia levels \> 92 mg/dl
* BMI \> 30
* At least a parent or a brother (or sister)affected by diabetes
* Pre-existing pregnancy with gestational diabetes

Exclusion Criteria:

* Pregnant women affected by pregestational diabetes
* Twin pregnancy
* Patients affected by pre-existing diseases in pregnancy (diabetes excluded)
* Patients affected by chronic disorders
B: Inclusion Criteria:

* BMI 30 or more
* Less than 20 weeks gestation
* member of Kaiser Permanente Northwest (NW)
* receive pre-natal care at Kaiser Permanente NW
* speaks English

Exclusion Criteria:

* no current treatment for cancer
* no bariatric surgery
* no current renal disease
* no multiple birth anticipated
* no hyperemesis requiring hospitalization
* no diabetes (type 1 or 2)
C: Inclusion Criteria:

1. Establish prenatal care at 6 - 16 weeks gestation
2. 18-49 years of age
3. Receive their entire prenatal care at the Resident Obstetrics Clinic
4. English and/or Spanish speaking
5. Singleton gestation.

Exclusion Criteria:

1. Establish prenatal care \>16 weeks gestation
2. Non-English or non-Spanish speaking
3. Multiple gestation pregnancy
4. BMI \> 40
5. Preexisting diabetes, untreated thyroid disease, or hypertension requiring medication or other medical conditions that might affect body weight
6. Delivery at institution other than CMC-Main
7. Pregnancy ending in a premature delivery (\< 37 weeks)
8. Limited prenatal care (\<4 visits)
D: Inclusion Criteria:

* Obese pregnant women: BMI \> 30 Kg/cm2
* first trimester fast glycaemia \< 126 mg/dl
* single pregnancy

Exclusion Criteria:

* Pregnant women with BMI \< 30 Kg/cm2
* first trimester fast glycaemia \> 126 mg/dl
* previous gestational diabetes
* twin pregnancy
* pregestational diabetes
* associated therapies with corticosteroids

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Effects of Music Therapy on Women's Anxiety Before and During Cesarean Delivery
Brief Summary: The purpose of the study is to determine if listening to your choice of music with a portable mp3 player before and after a cesarean section for delivery of a baby will decrease the patient's anxiety level.


Options:
A: Inclusion Criteria:Women age 18 and older with a history of one prior Cesarean delivery that are scheduled for a repeat Cesarean delivery under regional anesthesia, or women who are undergoing a primary cesarean section will be eligible to participate.

-

Exclusion Criteria:Women with cardiovascular disease, chronic hypertension, insulin dependent diabetes mellitus, multiple gestation pregnancies, psychiatric disorders, and fetal anomaly.

-
B: Inclusion Criteria:

* Delivery by scheduled cesarean section at Brigham and Women's Hospital

Exclusion Criteria:

* Answer "yes" to the question: "Has any provider talked to you this pregnancy about medications for pain control after your c-section?"
* History of opiate abuse
* Use of chronic opiates, benzodiazepines or gabapentin
* History of chronic pain
* Cesarean hysterectomy
* Vertical skin incision
* Myomectomy at the time of cesarean section
* Non English-speaking
* Patient of the investigator performing the recruitment
C: Inclusion Criteria:

* Pregnant women undergoing cesarean delivery

Exclusion Criteria:

* Cesarean hysterectomy
* Intraoperative accidental injury to urinary or gastrointestinal organs
* Postoperative admission to intensive care unit (ICU)
* Postoperative intraperitoneal drain placement
* Unable to understand and follow oral/written instructions
* Severe neuromuscular or circulatory disorders
* Pulmonary diseases
D: Inclusion Criteria:

* greater than 36 weeks gestation
* primary C/S with Epidural for labor problems or breech presentation
* Repeat C/S with spinal

Exclusion Criteria:

* less than 36.0 week gestations
* vertical skin incisions
* classical or vertical hysterotomy incisions
* failed vaginal births after C/S (VBAC)
* past history of drug or alcohol abuse
* positive drug screens unless medical prescribed drugs
* general anesthesia
* Caesarean Hysterectomy
* primary C/S with spinal anesthesia

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prolonged Exposure for PTSD Among OIF/OEF Personnel: Massed vs. Spaced Trials
Brief Summary: The purpose of this study is 1) to evaluate whether massing 10 PE sessions in 2 weeks (massed trials; M-PE) is more efficacious than Minimal Contact control (MCC); 2) whether the massed sessions format retains the efficacy of treatment compared to 10 PE sessions spaced over 8 weeks (spaced trials; S-PE), and 3) to evaluate for the first time the efficacy of the 10 PE sessions delivered in 8 weeks in an active duty population by comparing it to an active comparison condition, Present-Centered Therapy (PCT).


Options:
A: Inclusion Criteria:

* Adults survivors of traumatic events

Exclusion Criteria:

* Traumatic brain injury
* Lifetime psychosis
* Life time (prior) PTSD
* Medical conditions forbidding SSRIs
B: Inclusion Criteria:

* High levels of PTSD symptoms (i.e. Scores on the PSS-I \> 7 points)
* High levels of appetitive aggression (i.e. Scores on the Appetitive Aggression Scale (AAS) \> 8 points)
* participants are recruited through the community based re-integration program

Exclusion Criteria:

* acute psychotic episode
C: Inclusion Criteria:

* Adult male and female active-duty OIF/OEF military personnel and recently separated OIF/OEF veterans ages 18-65 seeking treatment for PTSD
* Diagnosis of PTSD determined by a clinician-administered Posttraumatic Stress Scale (PSS-I).

Exclusion Criteria:

* Current bipolar disorder or other psychotic disorder (as determined by the evaluator conducting the patient interview and medical record review)
* Current alcohol dependence (as determined by the AUDIT)
* Evidence of a moderate or severe traumatic brain injury (as determined by the inability to comprehend the baseline screening questionnaires)
* Current suicidal ideation severe enough to warrant immediate attention (as determined by the Scale for Suicidal Ideation)
* Other psychiatric disorders severe enough to warrant designation as the primary disorder
D: Inclusion Criteria:

* Must meet criteria for Major Depression.
* Must be free of other mental or physical disorders that could cause depression, and also free from conditions that would typically exclude participants from trials involving pharmacologic antidepressants.
* Cannot be receiving other treatments or require immediate clinical attention.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections
Brief Summary: This randomised, controlled, double blinded clinical study investigates the safety and efficacy of the combination of albendazole, ivermectin and praziquantel in the treatment of children aged 5-18 years co-infected with lymphatic filariasis, schistosomiasis and soil-transmitted helminthiasis.


Options:
A: Inclusion Criteria:

* Residing in or around Pondicherry and adjoining Tamilnadu areas
* Night blood microfilaria counts \> 10 mf/ml by membrane filtration
* No history of treatment for filarial infection for the last two years at least
* Willing for home visits by the staff of the center
* Willing to give written informed consent

Exclusion Criteria:

* Body weight less than 30 kg
* Hepatic or renal disease as evidenced by clinical or biochemical abnormalities. - concurrent illness like hypertension, diabetes mellitus, cardiac conditions and epilepsy requiring chronic medication
* Psychiatric illness
* Patients under tetracycline or doxycycline therapy
* History of de-worming by albendazole or other anti-helminthic during last one year
* Pregnancy or lactation
B: Inclusion Criteria:

* Those who will be in class one to six by the time of study
* Aged 5-18 years and found infected with either SCH, any STH or LF for treatment groups 1,2 or 3 or infected with both SCH and LF for treatment group 4 and infected with all the three for treatment group 5
* Who are willing and consent and whose parents will consent, will be included in the study.

Exclusion Criteria:

* Those with acute and chronic diseases other than the targeted infections and those with a history of any serious adverse drug reactions will not be included in the study.
* Children with total bilirubin \> 50µmol/L and ALAT (Alanine transferase) \> 70IU/L will not qualify for recruitment.
C: Inclusion Criteria:

* understand and sign informed consent
* willing to undergo night blood sampling every 6 months for 2 years
* Age 18 to 55 years
* Haemoglobin of equal or above 9g/dl
* Microfilarial level of equal or above 80mg/dl

Exclusion Criteria:

* Non- consenting
* Pregnancy or lactation
* Treatment with albendazole or ivermectin within the previous 6 months
* Known allergy to the study drugs
D: Inclusion Criteria:

* Men and women 18-65 years
* \>50 mf/ml in finger stick blood samples
* Willing to give informed consent

Exclusion Criteria:

* Prior treatment for LF within last 5 years
* Pregnant (do pregnancy test)
* Hemoglobin \< 7 g/dl
* permanent disability, serious medical illness that prevents or impedes study participation and/or comprehension
* AST/ALT and creatinine \> 1.5 upper limit of normal.
* Urine dipstick with glucose ≥ 2+ and/or protein ≥ 2+

Answer: B